Efficacy of asciminib in chronic phase CML patients with T315l mutations

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523491-23-00

Enrollment

Registered

2026-06-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia

Brief summary

rate of MR2 at 12 months measured by BCR::ABL1 via PCR

Detailed description

Reduction of the size of the T315I positive BCR::ABL1 clone by NGS measurement, Rate of molecular response assessed by BCR-ABLIS monitoring at and by 6, 18, 24 months, Progression-free survival, probabilities of CML-related death, overall survival at and by end of study, Quality of life at enrolment and months 3, 6, 9, 12, 18, and 24 after start with asciminib

Interventions

DRUGAsciminib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
rate of MR2 at 12 months measured by BCR::ABL1 via PCR	—

Secondary

Measure	Time frame
Reduction of the size of the T315I positive BCR::ABL1 clone by NGS measurement, Rate of molecular response assessed by BCR-ABLIS monitoring at and by 6, 18, 24 months, Progression-free survival, probabilities of CML-related death, overall survival at and by end of study, Quality of life at enrolment and months 3, 6, 9, 12, 18, and 24 after start with asciminib	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 24, 2026